# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A**

(Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed l	by the R	egistrant ⊠	Filed by a Party other than the Registrant $\ \Box$		
Check	the app	ropriate box:			
	Prelim	inary Proxy Statement			
	Confi	dential, For Use of the	Commission Only (as permitted by Rule 14a-6(e)(2))		
	Defini	tive Proxy Statement	ive Proxy Statement		
$\boxtimes$	Defini	tive Additional Material	s		
	Solicit	ing Material Pursuant to	§ 240.14a-12		
		T'NI	ANITA DILADAGA CELITEICAI C INC		
		EIN.	ANTA PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter)		
			(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)		
Payme	ent of fil	ing fee (Check the appro	opriate box):		
$\boxtimes$	No fe	e required			
	Fee c	omputed on table below	per Exchange Act Rules 14a-(6) (i) (1) and 0-11.		
	(1)	Title of each class of s	ecurities to which transaction applies:		
	(2)	Aggregate number of	securities to which transactions applies:		
	(3)		underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the and state how it was determined):		
	(4)	Proposed maximum ag	ggregate value of transaction:		
	(5)	Total fee paid:			
	Fee p	aid previously with preli	minary materials.		

(1)	Amount Previously Paid:		
(2)	Form, Schedule or Registration Statement No.: Filing Party: Date Filed:		
(3)			
(4)			



C/O MEDIANT COMMUNICATIONS P.O. BOX 8016, CARY, NC 27512-9903

### Enanta Pharmaceuticals, Inc. Important Notice Regarding the **Availability of Proxy Materials**

#### Stockholders Meeting to be held on March 03, 2022

For Stockholders of record as of January 07, 2022

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



## For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/ENTA

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before February 18, 2022.

To order paper materials, use one of the following methods.



## INTERNET

www.investorelections.com/ENTA





When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

\*If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

#### Enanta Pharmaceuticals, Inc.

Meeting Type: Annual Meeting of Stockholders
Date: Thursday, March 03, 2022
Time: 04:00 PM, Eastern Time
Place: Annual Meeting to be held Live via the internet

Please visit www.proxydocs.com/ENTA for more details

You must register to attend the meeting online and/or participate at www.proxydocs.com/ENTA

SEE REVERSE FOR FULL AGENDA

## **Enanta Pharmaceuticals, Inc.**

Annual Meeting of Stockholders March 3, 2022

## THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR PROPOSALS 1, 2, 3 AND 4

#### PROPOSAL

- To elect two Class III directors to serve until the 2025 Annual Meeting of Stockholders or until their respective successors are elected and qualified.
  - 1.01 Mark Foletta 1.02 Lesley Russell
- 2. To approve an amendment to our 2019 Equity Incentive Plan.
- 3. To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.
- 4. To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2022 fiscal year.

To transact any other business that may properly come before the meeting or any adjournment of the meeting.